Lakefront Biotherapeutics NV
LKFTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeLakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. At a $1.87B market cap, Lakefront Biotherapeutics NV ranks as a small-cap company within healthcare. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
Market Cap
$1.87B
Beta
0.12
P/E (TTM)
3.29
P/E (Fwd)
-9.43
EPS (TTM)
$8.61
EPS (Fwd)
$-3.01
ROE
16.3%
ROA
10.7%
Cash
$2.98B
Total Debt
$6.4M
Free CF
$211.0M
52W Change
-2.9%
Annual Financials
Cash vs Debt
With $2.98B in cash and $6.4M in debt, LKFT maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $211.0M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 16.3%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 10.7% further supports the picture of efficient asset utilization. Revenue has grown from $241.2M (2022) to $1.11B (2025), reflecting a 361% increase over the period.
LKFT's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Lakefront Biotherapeutics NV and its sector.